NEW YORK, Jan. 08, 2019 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) ( AXIM), a world leader in cannabinoid research and development, today announced the appointment of John W. Huemoeller II as the company’s new Chief Executive Officer (“CEO”).
John W. Huemoeller II has served on the Board of Directors of AXIM® Biotech as Chairman of the Audit Committee since July 2017 and brings over three decades of executive leadership and investment experience to AXIM’s executive team.
- Warning! GuruFocus has detected 1 Warning Sign with AXIM. Click here to check it out.
- AXIM 30-Year Financial Data
- The intrinsic value of AXIM
- Peter Lynch Chart of AXIM
“I am honored to take on this role within such an industry-leading organization and plan to propel the company forward in its mission of bringing novel cannabinoid-based